

LRG1

Native Human Leucine-rich Alpha-2-Glycoprotein

Catalog No.	CRA167A CRA167B	Quantity:	100 µg 1 mg
Alternate Names:	Leucine-rich alpha-2-glycoprotein, LRG		
Description:	<p>Leucine-rich alpha-2-glycoprotein is an acute phase protein with levels elevated in patients with bacterial infections; interestingly, during the inflammatory response, LRG1 levels are not correlated with CRP levels. LRG1 binds cytochrome c, an initiator/amplifier of programmed cell death (apoptosis), and by binding cytochrome c, is thought to play a role in cell survival.</p> <p>LRG1 is a biomarker associated with several cancers, including non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Recent studies have shown it is three-fold more abundant in ovarian cancer serum compared to non-cancer control serum. LRG1 levels are only moderately correlated with CA125 levels.</p> <p>Elevated levels of LRG1 in cerebral spinal fluid are being studied as markers for the early diagnosis of Parkinson's disease and progressive supranuclear palsy. In normal plasma LRG1 has a concentration of 21-50 ug/ml</p>		
UniProt ID:	P02750		
Source:	Human plasma		
Molecular Weight:	50 kDa		
Formulation:	Lyophilized from 20 mM Tris-HCl, 20 mM NaCl, pH 7.5		
Purity:	≥95% by SDS-PAGE analysis		
Extinction Coefficient:	$E^{0.1\%}_{280\text{nm}} = 0.70$		
Reconstitution:	Centrifuge vial prior to opening. Add sterile, distilled water to 0.1-1.0 mg/ml. Aliquot and freeze unused portion.		
Storage & Stability:	Store at -20°C to -80°C for up to 1 year. Upon reconstitution, prepare working aliquots and store at -20°C to -80°C. Avoid repeated freeze-thaw cycles.		
Infectious Disease Statement:	Prepared from plasma shown to be non reactive for HbsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.